Deficiency in CD22, a B cell–specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies

TL O'Keefe, GT Williams, FD Batista… - The Journal of …, 1999 - rupress.org
TL O'Keefe, GT Williams, FD Batista, MS Neuberger
The Journal of experimental medicine, 1999rupress.org
CD22 is a B cell–specific transmembrane glycoprotein that acts to dampen signals
generated through the B cell antigen receptor (BCR): B cells from CD22-deficient mice give
increased Ca2+ fluxes on BCR ligation. Here we show that this B cell hyperresponsiveness
correlates with the development of autoantibodies. After the age of eight months, CD22-
deficient mice developed high titers of serum IgG directed against double-stranded DNA;
these antibodies were of multiclonal origin, somatically mutated, and high affinity. Increased …
CD22 is a B cell–specific transmembrane glycoprotein that acts to dampen signals generated through the B cell antigen receptor (BCR): B cells from CD22-deficient mice give increased Ca2+ fluxes on BCR ligation. Here we show that this B cell hyperresponsiveness correlates with the development of autoantibodies. After the age of eight months, CD22-deficient mice developed high titers of serum IgG directed against double-stranded DNA; these antibodies were of multiclonal origin, somatically mutated, and high affinity. Increased titers of antibodies to cardiolipin and myeloperoxidase were also noted. The results demonstrate that a single gene defect exclusive to B lymphocytes is, without additional contrivance, sufficient to trigger autoantibody development in a large proportion of aging animals. Thus, CD22 might have evolved specifically to regulate B cell triggering thresholds for the avoidance of autoimmunity.
rupress.org